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The  human  diet  contains  a  vast  number  of  dietary  phenolic  compounds  of  which
vitamin E represents only one class. Vitamin E  is  a generic  name  for  all  substances
exerting  the  biological  functions  of  a-tocopherol.  The  two  quantitatively  most
important E vitamers are a- and g-tocopherol (a-T and g-T). The fat soluble vitamin E is
absorbed and transported in  the circulation  to the liver where a-T is preferentially  re-
secreted into the bloodstream while the other vitamers are degraded by cytochrome  P450
enzymes  to  the  water-soluble  carboxyethyl  hydroxychroman  (CEHC)  metabolites
excreted in the urine. Thus, a-T blood concentrations  are usually  4-10  times  higher
than those of g-T. Vitamin  E is  mainly  recognized  to  protect  cell  components  from
oxidative damage, but has also been reported to inter alia control gene expression  and
cellular signalling pathways.
This thesis aimed at investigating the effects  of dietary  phenolic  compounds  on the
bioavailability  of  vitamin  E  in  model  studies.  To  this  purpose,  polyphenols  were
incorporated into standardized, semi-synthetic diets and fed to male  Sprague-Dawley
rats for 4 weeks. Blood plasma, liver and lung tissue concentrations of a-T and g-T were
determined. The sesame lignan sesamin and cereal  alkylresorcinols  greatly  increased
the bioavailability of g-T, but not a-T, in all tissues. In contrast, the flaxseed  lignan
secoisolariciresinol  diglucoside  reduced  the  bioavailability  of  both  tocopherols.  The
flavanols  (+)-catechin  and  (-)-epicatechin  and  the  preservative  butylated
hydroxytoluene (BHT) markedly enhanced the bioavailability of a-T in  all  analysed
tissues. Curcumin and the tested anthocyanins and  phenolic  acids exerted only  minor,
inconsistent effects in different tissues in the rat model.  
In order to study the impact of selected polyphenols on the enzymatic degradation of
vitamin E, HepG2 cells were incubated  together  with  phenolic  compounds  in  the
presence of  tocopherols  and  the  formation  of  metabolites  was determined.  Sesamin
almost  completely  inhibited  tocopherol  side-chain  degradation  and  cereal
alkylresorcinols inhibited it, dose-dependently, by  20-80%. BHT and (+)-catechin had
no effect on tocopherol-w-hydroxylase activity in HepG2 cells.
To verify the inhibition of g-T metabolism by sesame lignans  in humans, sesame oil
or  corn  oil  muffins  together  with  deuterated  d6-a-T  and  d2-g-T  were  given  to
volunteers.  Blood  and  urine  samples  were  collected  for  72  hours  and  analysed  for
deuterated  and  non-deuterated  tocopherols  and  their  metabolites.  Consumption  of
sesame oil muffins significantly reduced the urinary excretion of d2-g-CEHC.
Overall, the findings from this thesis show that dietary  phenolic  compounds  alter
vitamin E bioavailability in humans and animals through various mechanisms.
Keywords:  Bioavailability,  blood,  carboxyethyl  hydroxychromans,  CEHC,  cells,
cytochrome P450, CYP, HepG2, humans, livers, lungs, rats, tocopherols,  tocopherol-w-
hydroxylase, vitamin E.
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‘Vitamin E’ kallas  en grupp  essentiella  näringsämnen  som alla har samma biologiska
funktion  som  a-tokoferol.  De  åtta  substanserna  med  E-vitamin-aktivitet  som
förekommer i naturen, a-, b-, d- och g-tokoferol och a-, b-, d- och g-tokotrienol,  bildas
enbart av växter och måste därför tillföras kroppen med kosten. Huvudfunktionen av E-
vitamin  är  att,  som  antioxidant,  skydda  andra  molekyler  mot  fria  radikaler.  Fria
radikaler är mycket reaktiva föreningar som bildas i  kroppen  vid  olika  fysiologiska
processer och som utlöser kedjereaktioner som förstör  viktiga  cellkomponenter  som
t.ex. membranlipider,  proteiner  och  DNA. Därför anses  vitamin  E skydda  mot  olika
kroniska sjukdomar, t.ex. hjärtinfarkt, stroke och cancer, som förmodligen  uppstår  bl.a.
på  grund  av  inverkan  av  fria  radikaler.  Epidemiologiska  studier  visar  ett  samband
mellan ett högt intag av vitamin E samt höga blodvärden av E vitamin  och en minskad
risk för kroniska sjukdomar.
Konkreta  rekommendationer  angående  intag  av  en  bestämd  mängd  och  form  av
vitamin E som kan skydda mot insjuknande kan inte ges i nuläget. Det grundar sig bl.a.
på att E-vitaminets biotillgänglighet, dvs. mängden av en viss dos  E vitamin  som efter
intag  är  tillgänglig  för  fysiologiska  processer  i  kroppen  påverkas  av  ett  stort  antal
faktorer.  Som  exempel  kan  nämnas  typen  och  mängden  av  samtidigt  konsumerade
fenoliska  substanser  (antioxidanter)  och  metabolismen  av  E-vitaminet  till
vattenlösliga metaboliter och deras utsöndring i urinen. Vår kost innehåller utöver E
vitamin ett stort antal fenoliska  ämnen, framför allt  växtsubstanser,  som kan utöva  en
rad biologiska effekter i kroppen.
I  denna  avhandling  har  effekter  av  fenoliska  substanser  på  E-vitaminets
biotillgänglighet undersökts med hjälp av  olika  modellstudier.  Råttor har matats med
fenoliska ämnen och blodplasma, lever och lungor  har analyserats  för halten  av de två
viktigaste formerna av E-vitamin, a- och g-tokoferol. Jag har identifierat  ämnen  som
betydlig  förbättrar  E-vitaminets  biotillgänglighet,  t.ex.  sesamin,  en  väsentlig
beståndsdel av sesamfrö och sesamolja, alkylresorcinoler som  förekommer i fullkorns-
cerealier och flavanolerna (+)-catechin och (–)-epicatechin  som finns  i te, choklad  och
många  frukter.  I  motsats  till  dessa  substanser  försämrade  secoisolariciresinol
diglukosid, en viktig beståndsdel av linfrö och linfröolja,  biotillgängligheten  av både
a- och g-tokoferol.
Därutöver undersöktes, i odlade leverceller, några utvalda växtfenolers effekt på E-
vitamins enzymatiska nedbrytning till  vattenlösliga  metaboliter.  Sesamin förhindrade
nästan  fullständigt  omvandlingen  av  g-tokoferol  till  metaboliter,  medan
alkylresorcinoler gjorde det på ett dos-beroende sätt.
Inhiberingen av g-tokoferol-metabolismen  med  hjälp  av  sesamlignaner  studerades
också i ett humanförsök. Intag av muffins bakade med sesamolja ledde till en betydligt
minskad utsöndring av g-tokoferol-metaboliter i urinen.
Resultaten  av  undersökningarna  i  denna  doktorsavhandling  visar  att  fenoliska
substanser i maten kan påverka E-vitaminets biotillgänglighet med hjälp av ett antal
olika mekanismer.Zusammenfassung
Vitamin  E  ist  ein  Sammelbegriff  für  alle  chemischen  Verbindungen  mit  der
biologischen Wirkung  von  a-Tokopherol.  Die acht natürlich  vorkommenden  Vitamin
E-Verbindungen, a-, b-, d- und g-Tokopherol  und  a-, b-, d- und  g-Tokotrienol,  werden
ausschließlich von Pflanzen gebildet und  müssen  daher dem Körper über die Nahrung
zugeführt werden.  Die Hauptfunktion  von  Vitamin  E ist  es, als  Antioxidans  andere
Moleküle  vor  freien  Radikalen  zu  schützen.  Freie  Radikale  sind  extrem  reaktive
Verbindungen, die im Körper als Nebenprodukte physiologischer  Prozesse  entstehen
und Kettenreaktionen auslösen die zur Zerstörung wichtiger Zellstrukturen, wie z.B. der
Membranlipide, Proteine und DNS, führen. Aus diesem Grund wird dem Vitamin E eine
schützende Rolle  bei  der  Vorbeugung  verschiedener  chronischer  Erkrankungen,  wie
z.B. Herzinfarkt, Schlaganfall und Krebs, zugesprochen, bei  deren  Entstehung  freie
Radikale  vermutlich  eine  zentrale  Rolle  spielen.  Darüber  hinaus  stützen
epidemiologische  Studien  einen  Zusammenhang  zwischen  einer  hohen  Vitamin  E-
Zufuhr  sowie  hohen  Vitamin  E-Blutspiegeln  und  einem  verminderten  Auftreten
chronischer Erkrankungen.
Konkrete Empfehlungen bezüglich der  Zufuhr  einer  bestimmten  Menge  und  Form
von Vitamin E die vor Erkrankung schützen kann, sind nach dem heutigen Stand der
Forschung nicht verfügbar. Dies gründet sich u.a. darauf dass die Bioverfügbarkeit  von
Vitamin E, also diejenige Menge einer bestimmten Dosis  die  nach  dem  Verzehr dem
Körper für biologische Prozesse zur Verfügung  steht,  von  einer Vielzahl von  Faktoren
beeinflusst  wird.  Als  Beispiele  können  hier  u.a.  gleichzeitig  aufgenommene
phenolische  Verbindungen  (Antioxidantien)  oder  der  Abbau  von  Vitamin  E  zu
wasserlöslichen Endprodukten und deren Ausscheidung mit dem  Urin genannt  werden.
Die  menschliche  Nahrung  enthält  neben  Vitamin  E  noch  eine  Vielzahl  weiterer
phenolischer  Verbindungen,  überwiegend  pflanzlicher  Herkunft,  die  im  Körper  eine
Reihe biologischer Wirkungen entfalten können.
Die vorliegende Doktorarbeit beschäftigt sich mit den Auswirkungen von über  die
Nahrung  zugeführten  phenolischen  Verbindungen  auf  die  biologische  Verfügbarkeit
von  Vitamin  E  unter  Zuhilfenahme  verschiedener  Modellstudien.  Hierzu  wurden
phenolische Verbindungen an Ratten verfüttert  und  anschließend  die Gehalte der zwei
quantitativ  wichtigsten  Vitamin  E-Formen,  nämlich  a- und g-Tokopherol,  im
Blutplasma,  Leber-  und  Lungengewebe  bestimmt.  Dabei  wurden  Verbindungen
identifiziert die die biologische Verfügbarkeit  von  Vitamin  E deutlich  erhöhen,  wie
z.B. Sesamin, ein wesentlicher Bestandteil  von  Sesamsamen und  -öl, Alkylresorcinole,
die besonders in Vollkorngetreide enthalten sind, sowie die  in  Tee, Schokolade  und
vielen Früchten enthaltenen Flavanole (+)-Catechin  und  (-)-Epicatechin. Im Gegensatz
zu  diesen  Stoffen  verschlechterte  Secoisolariciresinoldiglukosid,  ein  quantitativ
bedeutender Bestandteil von Leinsamen und -öl, die Bioverfügbarkeit von a- und  g-
Tokopherol.
Weiterhin  wurden  die  Auswirkungen  von  ausgesuchten  Polyphenolen  auf  den
enzymatischen Abbau von  Vitamin E zu seinen  wasserlöslichen  Metaboliten  in einem
Zellmodell untersucht. Sesamin verhinderte hier die Umwandlung von g-Tokopherol  zu
seinen  Metaboliten  fast  vollständig,  während  die  Alkylresorcinole  dies  in
Abhängigkeit von der verabreichten Dosis taten.
Die Hemmung des Metabolismus von g-Tokopherol  durch Sesamlignane  wurde auch
am Menschen untersucht. Der Verzehr von  mit Sesamöl gebackenen  Muffins  führte zu
einer deutlich geringeren Ausscheidung von g-Tokopherol-Metaboliten im Urin.
Die  Untersuchungsergebnisse  dieser  Doktorarbeit  zeigen,  dass  phenolische
Nahrungsbestandteile  die  biologische  Verfügbarkeit  von  Vitamin  E  mittels  einer
Anzahl verschiedener Mechanismen beeinflussen können.Contents
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Vitamin E
In 1922, Herbert Evans and Katherine Bishop discovered what they called ‘factor
X’, an essential factor for successful reproduction in rats (Evans & Bishop, 1922).
Three years later, this ‘factor X’ was assigned its vitamin status and the letter E,
being the next serial alphabetical designation after the preceding discovery of the
vitamins A-D (Mason, 1977). A decade later, Evans and co-workers isolated an
alcohol  with  the  biological  activity  of  vitamin  E  from  wheat  germ  oil  and
proposed the name a-tocopherol (Greek: tokos = child birth; phero = to bear; and
-ol, indicating an alcohol) (Evans, Emerson & Emerson, 1936).
Structures and stereochemistry
Vitamin E is a generic name for all substances exerting the biological activity of
a-tocopherol  (a-T). The  eight  recognized  natural  vitamin  E  compounds
(subsequently referred to as ‘vitamers’) consist of a chroman head substituted with
a 16-carbon side-chain and are classified into tocopherols, with a saturated phytyl
side-chain, and tocotrienols, with an unsaturated isoprenoid side-chain with three
isolated double bonds. The Greek letters a-, b-, g-, and d- are added as prefixes to
denote the number and positions of methyl groups linked to  the chroman head
(Figure 1). The phytyl side chain of the tocopherols has three chiral centers at
positions 2, 4', and 8', which can be either in the R- or S-conformation, giving
rise to eight different stereoisomers (RRR, RSR,  RRS,  RSS,  SRR,  SSR,  SRS,
and SSS) for each tocopherol. The tocotrienols have only one chiral  center at
position 2 and can therefore only be in R- or S-configuration. However, the double
bonds at the 3'  and 7'  positions  of the tocotrienol side-chain give rise to  four
cis/trans geometrical isomers. Hence, at least in theory, eight isomers are possible
for each tocotrienol (Kamal-Eldin & Appelqvist, 1996).
Occurrence and dietary intake
Vitamin  E  is  exclusively  synthesised  by  photosynthetic  organisms.  Plants
accumulate a-T in their green tissues, while g-T and d-T are mainly present in
seeds, and tocotrienols are predominant in cereal grains and palm  oil  (Lampi,
Kamal-Eldin & Piironen, 2002; Munne-Bosch & Alegre, 2002). The  richest
sources of vitamin E are vegetable oils, with wheat germ, safflower, and sunflower
oils being particularly rich in a-T, and soybean, corn, and sesame oils  in  g-T.
Other good sources of vitamin E include lipid-rich plant parts such as nuts, seeds
and grains. The dietary intake of vitamin E in Western diets is mainly from fats
and oils used in margarine, mayonnaise, salad dressings, and also from fortified
foods such as breakfast cereals and  fruit  juices.  In  contrary to  other  Western
populations  where  a-T is the predominant form in the diet, g-T is the major
dietary form of vitamin E in the USA due to the widespread use of soybean and
corn oils (Packer & Obermüller-Jevic, 2002). The naturally occurring tocopherols
exist solely as RRR-stereoisomers. Synthetic tocopherols, on the other hand, are
composed of an equimolar mixture of  all  eight  stereoisomers, a  so-called all12
racemic (all rac) mixture. The vitamer most frequently used in supplements and
fortified foods is a-T (mostly all rac-a-T, but also RRR-a-T); often in the form
of esters with acetate, succinate or  nicotinate to  improve  its  storage stability
(Packer & Obermüller-Jevic, 2002).
Human plasma Activity based on rat assay
Common Name R1 R2 concentrations IU/mg
1 Relative to a-T
a-Tocopherol CH3 CH3 ~25-32 mM
2 1.49 100
b-Tocopherol CH3 H ~0.4 mM
3 0.75 50
g-Tocopherol H CH3 ~1.4-4.3 mM
2 0.15 10
d-Tocopherol H H ~0.3 mM
2 0.05 3
a-Tocotrienol CH3 CH3 n.d.
4 0.75 50
b-Tocotrienol CH3 H n.d.
4 0.08 5
g-Tocotrienol H CH3 n.d.
4 ? ?
d-Tocotrienol H H n.d.
4 ? ?
Figure 1. Chemical structures and methyl positions of  the  eight  naturally  occurring
forms of vitamin E and their biological activities.
1One IU (international unit) is defined as the biological  activity  of  1  mg  all  rac-a-
tocopheryl acetate (Hoppe & Krennrich, 2000).
2(Hensley et al., 2004).
3(Cooney et al., 2001).
4Tocotrienols  are  usually  not  detectable  in  plasma.  Supplementation  with  250  mg
tocotrienols/day for 8 weeks did  not  raise  their  plasma  concentrations  above  1  mM
(O'Byrne et al., 2000).
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Absorption, transport, and metabolism
On intake, the esterified vitamin is rapidly hydrolysed in the gut, thus releasing
the free form. The intestinal absorption of vitamin E generally parallels the
absorption of dietary fat (Figure 2). In humans, only a fraction, most likely ~15-
45%, of the ingested vitamin E is absorbed and the remainder excreted with  the
faeces (Traber & Sies, 1996; Traber, 2000). The liver secretes bile acids into the
small intestine to aid the digestion of lipids and the formation of mixed micelles.
Although dietary fat is needed to aid the absorption of vitamin E, the amount of
dietary fat is of minor importance and even low-fat diets grant a sufficient uptake
of the vitamin (Parks & Traber, 2000). Integrated in micelles, vitamin E is taken
up into the enterocytes by passive diffusion. Unlike other lipid soluble vitamins,
vitamin E has no specific plasma transport protein. In order to be transported in
the aqueous environment of the circulation, vitamin E is incorporated into a type
of lipoprotein, the chylomicrons, which are secreted into the lymphatic system by
the intestinal cells. The chylomicrons pass through the  thoracic duct  into  the
systemic circulation where they come in contact with  lipoprotein  lipase,  an
enzyme located on the surface of the vascular endothelium. Endothelial lipoprotein
lipase decomposes the chylomicrons and transfers a fraction of the  transported
vitamin E to tissues.  Vitamin E  is  also transferred from chylomicrons to  high
density  lipoproteins  (HDL)  from  where  it  can  easily  be  distributed  to  all
circulating lipoproteins.  Chylomicron  degradation  ultimately  results  in  the
chylomicron remnants, which are taken up into the liver by  a receptor-mediated
process. Right to this point, the extent of vitamin E absorption and transport to
the liver appears to be similar for all vitamers (Figure 2, Kayden & Traber, 1993;
Traber & Sies, 1996; Traber, 2000).
Once vitamin E enters the liver, RRR-a-T is  preferentially secreted into  very
low density lipoproteins  (VLDL), facilitated by  the  action  of  a  cytosolic  a-
tocopherol transfer protein (a-TTP) with pronounced selectivity towards the 2R-
isomers (R-configuration at carbon 2; Figure 2). Hosomi  and co-workers (1997)
determined the affinities of a-TTP for some E-vitamers relative to that for RRR-
a-T and found the following lower values: RRR-b-T, 38%; RRR-g-T, 9%; RRR-
d-T, 2%;  SRR-a-T, 11%;  and  a-tocotrienol,  12%.  Interestingly, the  affinity
values for the tocopherols are comparable to their biological activities (Figure 1).
Consequently, a-TTP was proposed as the determinant of the biological activity
of the vitamers (Hosomi et al., 1997). The selective secretion of RRR-a-T into
the blood stream does, at least partly, explain why a-T concentrations are usually
4-10 times higher than those of g-T. Circulating VLDL, carrying relatively high
amounts of RRR-a-T and  significantly lower  amounts  of  the  other  vitamers
(including  the  non-RRR  isomers  of  a-T), may transfer vitamin E to  HDL,
undergo conversion to low density lipoproteins (LDL), and/or return to the liver as
VLDL  remnants  and  do,  thus,  increase the  RRR-a-T concentrations of  all
lipoproteins. Tissues with an LDL-receptor internalise LDL actively by a receptor-
mediated process, which represents a major route  of  vitamin  E  delivery  to
peripheral tissues where vitamin E is  mainly  located  in  the  lipid  layer  of
biological membranes (Wang &  Quinn,  2000). The mechanisms for vitamin  E14
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release from peripheral tissues are as yet unknown. Normal blood concentrations of
a-T and g-T in humans have been reported to be in the range of 25-30 mM and
1.3-4.3 mM, respectively (Figure 1). In  discarded human  surgical tissues,  the
proportions of g-T (as % of a-T), 31% in adipose tissue, 33% in vein, 38% in
muscle, and 53% in skin, were found to be appreciably higher than  in  blood
(Burton et al., 1998). The non-a-T vitamers that are retained in  the  liver  are
metabolised  and  excreted  (Traber,  2000;  Packer  &  Obermüller-Jevic, 2002;
Hensley et al., 2004).
The  lipid-soluble  vitamin  E  is  degraded  to  water-soluble  carboxyethyl
hydroxychroman (CEHC)  metabolites  by  side-chain  degradation  (Figure  3)
without modification of the chromanol head (Sontag & Parker, 2002). CEHC’s are
conjugated with glucuronic acid or sulphate to  increase their  solubility  and
excreted in the urine. Although the exact location of vitamin  E-metabolism has
not been determined yet, hepatocytes are likely to play a central role. It has been
shown that human hepatoblastoma cells (HepG2) and rat primary hepatocytes as
well as human and rat liver microsomes convert vitamin  E  to  CEHC’s (Parker,
Sontag & Swanson, 2000; Birringer, Drogan & Brigelius-Flohe, 2001; Birringer
et al., 2002; Brigelius-Flohé et al., 2002b; Sontag & Parker, 2002). The first step
in the metabolism  of  tocopherols and  tocotrienols consists  of  a  terminal  w-
hydroxylation of the side-chain by cytochrome P450 (CYP) isozymes (most likely
CYP4F2, but a role for CYP3A has also been proposed) followed by a stepwise
shortening of the tail by b-oxidation (Figure 3, Parker, Sontag & Swanson, 2000;
Birringer et al., 2002; Sontag & Parker, 2002) similar to  that of saturated and
unsaturated  fatty  acids  (see  biochemistry  textbooks  for  details).  In  vitro,
tocopherol-w-hydroxylase, the enzyme that initiates vitamin  E  metabolism,
showed similar binding  affinities for a-T and g-T,  but  exhibited much higher
catalytic activity towards g-T,  suggesting a central role for this  enzyme in  the
selective  retention  of  a-T  in  the  body  and  the  regulation  of  g-T  plasma
concentrations (Sontag &  Parker, 2002).  This  notion  is  further supported by
findings in human subjects showing that up to ~50% of  the  ingested  g-T  is
excreted in urine as the corresponding g-CEHC metabolite (Swanson et al., 1999),
while only 1-3% of the consumed a-T dose is converted to urinary  a-CEHC
(Schuelke et al., 2000). Furthermore, when Traber and co-workers compared the
urinary excretion of deuterated a-CEHC derived from RRR-a-T and all rac-a-T,
they found 2-4 times more “all rac”-metabolites  (Traber, Elsner  &  Brigelius-
Flohé, 1998). Previously, secretion into the bile was proposed to  be the major
route of vitamin E elimination (Kayden & Traber, 1993), but evidence from a rat
study, together with the recent discovery of the degradation and urinary excretion
of the vitamin suggests that biliary excretion only plays a minor role (Yamashita,
Takeda & Ikeda, 2000; Sontag & Parker, 2002). Likewise, only a small fraction of
the vitamin E secreted in bile is reabsorbed during enterohepatic circulation while
the remainder is excreted in faeces (Lee-Kim et al., 1988).16
Figure 3. Side-chain degradation  of tocopherols  to their 3'- and 5'-carboxychromanol
metabolites.
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Functions of vitamin E
When Evans and Bishop studied the duration of the oestrous cycle in response to
dietary changes in laboratory rats, they discovered that the absence of the then
unknown ‘factor X’,  later  designated vitamin  E,  resulted in  foetal death  and
resorption (Evans & Bishop, 1922). During the following years, a multitude  of
vitamin E deficiency syndromes were described in various species (Mason, 1977),
but no specific function could be  ascribed to  the  vitamin.  Decades later,  the
antioxidant activity of a-T was discovered and assumed to be its major function
in  vivo (Kamal-Eldin &  Appelqvist,  1996;  Brigelius-Flohé &  Traber, 1999).
Recently, other biological functions of vitamin E, unrelated to  its  antioxidant
properties, have been discovered. These include roles in cellular signalling,  gene
expression, immune response, and apoptosis, and are now considered to be of
importance (Azzi, Ricciarelli & Zingg, 2002; Brigelius-Flohé et al., 2002a).
Protection against free radicals as part of the antioxidant network
According to the definition by Barry Halliwell (1996), “A  free radical is  any
species capable of independent existence…that contains  one  or  more  unpaired
electrons, that is, one that is alone in an orbital.” Free radicals (reactive oxygen
species (ROS) like superoxide, hydroperoxide, peroxyl and hydroxyl radicals, and
reactive nitrogen species (RNS) like nitric oxide, etc.) are constantly produced in
the body as a result of physiological processes, such as xenobiotic metabolism,
aerobic respiration in mitochondria or disposal of infected cells by  phagocytes
(Ames, Shigenaga & Hagen,  1993).  Once formed,  radicals rapidly  react with
macromolecules  (e.g.  poly-unsaturated  fatty  acids,  lipoproteins,  proteins,
carbohydrates,  RNA,  DNA,  etc.), thus starting  self-propagating radical  chain
reactions, which alter or  destroy  the  structure and  function  of  important  cell
components. Alternatively, reactive species may react with  other free radicals to
form stable products or be scavenged by antioxidants, thus being transformed into
non-radical species, while the antioxidants become ‘antioxidant-radicals’, which
are much less reactive and do not efficiently attack adjacent macromolecules
(Halliwell, 1996).
The excess formation of free radicals, caused by an imbalance of oxidative and
antioxidative processes, leads to oxidative stress (Sies, 1997), which is believed to
be  at  the  basis  of  many  degenerative  diseases,  such  as  atherosclerosis,
cardiovascular disease (CVD), stroke, cancer, arthritis, and Alzheimer’s disease
(Davies, 1995). It has also been suggested that oxidative stress may not only be a
result but also a cause of diabetes mellitus type II and CVD (Ceriello &  Motz,
2004). The body defends itself against oxidative damage through an antioxidant
network in which vitamin E plays a central  role  (Packer &  Obermüller-Jevic,
2002).  a-T  is  the  major  lipid-soluble,  chain-breaking antioxidant  in  human
plasma (Burton, Joyce & Ingold, 1982) preventing the progression of free radical
reactions and lipid peroxidation, thereby protecting lipoproteins and  biological
membranes (Kamal-Eldin & Appelqvist, 1996; Brigelius-Flohé &  Traber, 1999;
Packer & Obermüller-Jevic, 2002). The excellent antioxidant properties of vitamin
E, which vary in degree for its different vitamers, are due to the rapid abstraction18
of a phenolic hydrogen from the hydroxyl group at the chromanol head during the
reaction with free radicals (Kamal-Eldin &  Appelqvist,  1994;  Kamal-Eldin &
Appelqvist, 1996;  Packer &  Obermüller-Jevic, 2002).  The  membrane-bound
tocopheroxyl radical (at the surface of the lipid-water interface) is  then reduced
back to tocopherol by ascorbate (vitamin C) in the aqueous phase (Packer, Slater
& Willson, 1979). The ascorbyl radical is,  in  turn,  regenerated to  ascorbate by
thiol (e.g. glutathione, dihydrolipoic acid, or thioredoxin)  or  polyphenol  (e.g.
flavonoids) antioxidants. The thiol antioxidants, eventually, are recycled by  the
conversion of NAD(P)H+H
+ to NAD(P)
+. This concept is likely to  apply to  the
tocotrienols as well,  although  the  relevance will  be  limited,  due  to  the  low
concentrations observed in tissues (Packer & Obermüller-Jevic, 2002).
The differences in reactivity of the vitamers in vitro can be explained by  two
main factors, namely inductive effects caused by electron-releasing substituents in
ortho- and/or para-positions to the phenolic hydrogen and stereo-electronic effects
due to  the  orientation of  these  substituents  towards the  aromatic plane.  The
presence of more methyl groups, especially in ortho- and para-positions, enhances
the antioxidant activity. Hence, a-T with its two ortho-methyl groups is expected
to be a better hydrogen donor than b- and g-T  with only one ortho-methyl group
each, which are expected to be better antioxidants than d-T with no ortho-methyl
substituent (Kamal-Eldin & Appelqvist, 1996). This concept of relative reactivity
becomes even more complicated when applied to the situation in vivo. In  the
body, antioxidant activity is not only determined by chemical reactivity, but also
by compartmentalisation and the kinetics of absorption, transport, metabolism,
and excretion. As a result of the chemical and biological characteristics described
above, the two basic requirements for a good in vivo chain-breaking E-vitamer are
a fully methylated phenolic  ring  and  stereochemistry with  a  2R-configuration
(Kamal-Eldin & Appelqvist, 1996).
Reactive nitrogen species, in particular nitric oxide, are formed endogenously by
inter  alia macrophages and endothelial cells and occur in large  amounts  in
cigarette smoke (Cooney et al., 1993). Cooney’s group demonstrated that g-T is
much more efficient than a-T in the detoxification of nitrogen dioxide (Cooney et
al., 1993). The superiority of g-T to  a-T  in  the  disposal  of  RNS  has  been
confirmed in subsequent experiments (Cooney et al., 1995; Christen et al., 1997).
In contrast to the structural requirements for the scavenging of ROS where the un-
substituted 5-position of g-T is a disadvantage, this structural feature promotes the
nitration of g-T to form 5-nitro-g-T. The nitration of a-T is not possible because
of the methyl substituent at carbon 5 (Hensley et al., 2004). RNS are known
contributors to carcinogenesis (Hofseth et al.,  2003), therefore g-T  may play a
specific role in cancer prevention that cannot be assumed by a-T (see below).19
Non-antioxidant functions
In addition to its important role as a free radical scavenger, vitamin E has recently
been recognised to affect cellular signalling,  gene  transcription,  and  enzyme
activity, in a manner independent of its antioxidant properties.
a-T,  specifically,  inhibits  smooth  muscle  cell  proliferation  and  platelet
aggregation via the inhibition of protein kinase C (PKC). PKC inhibition by a-T
has been observed in a number of different cell types (monocytes, macrophages,
neutrophils,  fibroblasts,  and  mesengial  cells)  and  is  mediated  by
dephosphorylation of the enzyme via an activation of protein phosphatase 2A. a-T
also decreases the release of the pro-inflammatory cytokine interleukin-1b via the
inhibition of the 5-lipoxygenase pathway (Azzi et al., 2000;  Azzi  &  Stocker,
2000; Ricciarelli, Zingg & Azzi, 2002; Rimbach et al., 2002).
The regulation of gene transcription by a-T has been reported for  several
proteins. a-T up-regulates the expression of  a-tropomyosin  and  inhibits  liver
collagen a1 gene expression. In rat liver cells, the expression of a-TTP  and its
mRNA are modulated as a result of vitamin E deficiency. a-T down-regulates the
expression of the scavenger receptors class  A  and  CD36  in  macrophages and
smooth muscle cells at a transcriptional level (Azzi et al., 2000; Azzi & Stocker,
2000; Ricciarelli, Zingg & Azzi, 2002; Rimbach et al., 2002).
In  animal  and  human  studies,  dietary  tocotrienols  (T3)  lowered  blood
concentrations of lipids, particularly cholesterol. Experiments in cell  cultures
revealed that a-T3 reduces the endogenous synthesis of cholesterol by inhibition of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting
enzyme in the biosynthesis of cholesterol. The reduction in enzyme activity and
the hypocholesterolemic effect of a-T3 was attenuated if a-T was co-administered
(Qureshi et al., 1997; Khor & Ng, 2000; Packer,  Weber &  Rimbach,  2001).
Recently, supernatant protein factor  (SPF),  a  protein  stimulating  cholesterol
biosynthesis, was shown to be identical with a-tocopherol-associated  protein
(TAP).  SPF/TAP  binds  a-T, translocates to the nucleus  and  activates  gene
expression.  Thus,  a-T  was  suggested  to  affect  cholesterol  homeostasis  via
SPF/TAP and the down-regulation of scavenger receptors (Porter, 2003).
Vitamin E in health and disease
A multiplicity of disorders, such as atherosclerosis, stroke, heart disease, cancer,
rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, diabetes mellitus
type I and II, and even obesity, to name a few, have been proposed to result from
or to result in an excess formation of free radicals (Davies, 1995; Keaney et al.,
2003; Maritim, Sanders & Watkins, 2003; Ceriello & Motz, 2004). Therefore, it
is a common belief that antioxidants, which are capable of detoxifying free radical
species, may be helpful in  the prevention and/or treatment of these conditions.
Also, the non-antioxidant functions of vitamin E give rise to a wide array  of
potential health effects. Discussing the role of  vitamin  E  with  respect to  the
pathophysiology of all of the aforementioned disorders would by  far exceed the20
scope of this introduction. For this reason, only two major diseases causing death
and morbidity that are frequently discussed in connection with vitamin E, namely
atherosclerosis and cancer, are described below.
Vitamin E and atherosclerosis
Atherosclerosis is a disorder affecting the arteries by thickening of the arterial wall,
thus causing narrowing and loss of elasticity of the blood vessels and ultimately
leading to thrombus formation and obstruction, thereby causing stroke, CHD and
the  like.  In  their  ‘oxidation  hypothesis  of  atherosclerosis’,  Steinberg  and
colleagues suggest a central role for oxidised LDL (oxLDL) in  the aetiology of
atherosclerosis (Steinberg et al., 1989). Some key events in  the development of
atherosclerosis are (i) entrapment and oxidative modification of LDL (initiated by
free radicals and macrophages) in the endothelial intima, (ii) uptake of oxLDL by
macrophages via scavenger receptors, subsequently transforming them into  foam
cells, (iii) smooth muscle cell proliferation (induced by oxLDL), and (iv) platelet
adhesion and aggregation (leading to obstructive thrombus formation) (Steinberg
et al., 1989; Berliner & Heinecke, 1996). a-T has been shown (1) to protect LDL
particles from oxidation, (2) to down-regulate the  expression  of  macrophage
scavenger receptors, thus reducing the uptake of oxLDL, (3) to  inhibit  smooth
muscle cell proliferation and (4) to reduce platelet adhesion and aggregation; (3)
and (4) are facilitated by inhibition of PKC activity (Azzi, 2002).
There is increasing evidence that g-T  may play a special role in the prevention
of atherosclerosis. A diet rich  in  g-T  (containing minor  amounts  of  other  E
vitamers) was more effective than a-T alone in the prevention of iron-induced
lipid peroxidation and occlusive thrombus formation in a rat model (Saldeen, Li
& Mehta, 1999). Hensley and co-workers confirmed these results and proposed the
superiority of g-T in the detoxification of RNS to be at the basis of this  effect,
supported by a clear association of thrombus formation and the appearance of 5-
nitro-g-T in the circulation (Hensley et al.,  2004). In line with  these findings,
reduced blood concentrations of g-T, but not  a-T,  have been found in  patients
suffering from coronary heart disease and myocardial infarction (Öhrvall, Sundlöf
& Vessby, 1996; Kristenson et al., 1997; Kontush et al., 1999; Ruiz Rejón et al.,
2002). However, high  a-T concentrations were associated with  a lower risk of
ischemic heart disease (Gey et al., 1991).
The  outcome  of  prospective  studies  assessing  the  effects  of  dietary
supplementation with a-T on cardiovascular events are inconclusive and have been
reviewed elsewhere (Jialal & Devaraj, 2002; Stocker et al., 2002). It may suffice to
say that, despite initial positive reports associating a high  intake of vitamin  E
with a reduction in CHD risk (Rimm et al.,  1993),  the  results  from  clinical
supplementation trials, reporting positive, negative, or no effects,  have  been
disappointingly inconsistent and do not allow for recommendations regarding the
supplementation of vitamin E with regard to atherosclerosis prevention (Jialal &
Devaraj, 2002; Stocker et al., 2002).21
Vitamin E and cancer
Although conclusive evidence from human intervention trials with  vitamin  E  is
still lacking, some promising findings suggest a protective role of supplemental
a-T on the incidence of and death from prostate cancer in smokers (Heinonen et
al., 1998; Chan et al., 1999). In support of these data, observational studies found
an association between high vitamin E  blood  concentrations, especially of g-T,
and a reduced incidence of prostate cancer (Giovannucci, 2000; Helzlsouer et al.,
2000). Similarly, patients suffering from cancer of the upper aero-digestive tract
had significantly lower g-T plasma levels than comparable controls (Nomura et
al., 1997). Gysin and colleagues (2002) found that g-T, more so than a-T or b-T,
inhibited the growth of prostate and colon cancer cells. In confirmation of these
findings,  g-T and also its metabolite g-CEHC  inhibited  prostate  cancer  cell
proliferation by ≥75%, while the respective a-forms only reduced cell growth by
<50% (Galli et al., 2004). In contrast to the multitude of in vitro and in vivo data
supporting a protective role for vitamin E, especially g-T, on  prostate cancer in
smokers, Schwenke, in an  extensive review of  the  breast cancer risk  and  its
relation to vitamin E, concluded that the scientific literature provides only modest
evidence for a protective effect (Schwenke, 2002). A variety of mechanisms have
been proposed to explain how vitamin E might exert its  beneficial effects on
cancer. These concepts include: protection of DNA from oxidative modification by
free radicals, detoxification of RNS, inhibition of tumour cell growth through cell
cycle arrest and apoptosis, and enhanced elimination of cancer cells by stimulation
of the immune system (Jiang et al., 2001; Kline et al., 2003).
Interactions of vitamin E with xenobiotic metabolism
In HepG2 cells, all tocopherols and tocotrienols (T3) activate the nuclear receptor
PXR (pregnane X receptor). PXR  regulates the expression of a variety of drug
metabolising enzymes, including cytochrome P450  isozymes.  The  activation of
PXR by vitamin E analogues followed the order  g-T3ªa-T3>d-T>a-T≥g-T in
vitro. g-T3 up-regulated CYP3A mRNA to a similar degree as rifampicin, a known
inducer of PXR and CYP3A (Landes et al., 2003). It was mentioned earlier that
initial w-hydroxylation is a key step in vitamin E metabolism and that the CYP
isozymes 3A and 4F2 were proposed to potentially catalyze this reaction (Parker,
Sontag & Swanson, 2000;  Sontag &  Parker, 2002). CYP3A  metabolises more
than 50% of the drugs currently used for therapy (Cholerton, Daly & Idle, 1992;
Kliewer, Goodwin & Willson, 2002). Hence, by  means  of  induction  of  drug
metabolising enzymes, vitamin E may enhance its own elimination, but also the
clearance of therapeutic drugs and other xenobiotics, posing a possible explanation
for  unexpected  negative  outcomes  in  clinical  trials  where  drugs  were  co-
administered with vitamin E (Traber, 2004).22
Dietary phenolic compounds – contribution to
human health
Occurrence and dietary intake
Vitamin E is only one of the many classes of phenolic compounds in the diet. The
vast majority of dietary phenolic compounds, often referred to  as polyphenols,
originate from plant foods (Scalbert & Williamson, 2000). In addition, synthetic
phenols are frequently added as preservatives to  lipid  rich foodstuffs (Leclercq,
Arcella  &  Turrini,  2000).  In  plants,  phenolic  compounds  fulfil  essential
physiological purposes, such as protecting from ultraviolet radiation, pathogens
and predators, contributing to their colour and flavour, and facilitating growth and
reproduction (Bravo, 1998; Harborne & Williams, 2000;  Heim,  Tagliaferro &
Bobilya, 2002). Several thousand of these natural compounds have been identified
in plants, with a large diversity in their structural features (Harborne & Williams,
2000). These may  be  grouped into  classes according to  the  shared structural
characteristics of their carbon skeletons. The main classes of natural polyphenols
comprise phenolic acids and derivatives, flavonoids, lignans, and stilbenes (Figure
4), as well as tannins and lignins (Shahidi & Naczk, 2003).
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Figure 4. Basic chemical structures of important subclasses of polyphenols.23
Phytochemicals are synthesized in the secondary metabolism of plants, therefore
sometimes  called  ‘secondary  plant  metabolites’,  and  stem  from  two  major
synthetic pathways: the shikimate and the acetate pathway  (Bravo,  1998).  All
plant phenolic compounds share one common feature, namely an aromatic ring
with at least one hydroxyl substituent, but may vary greatly in their complexity
from simple phenols to the highly polymerized tannins and lignins.  They occur
predominantly as conjugates with sugars (mono-, di-,  or oligosaccharides), with
glucuronic or galacturonic acids, or even with  other phenols that are linked to
hydroxyl groups or, less frequently, aromatic carbon atoms.  The principal sugar
residue is glucose while others, e.g. galactose,  rhamnose, xylose  or  arabinose
residues, are also encountered (Bravo, 1998). The structural diversity of phenolic
compounds results in a plethora of phytochemicals ingested by man. It would be
almost impossible to describe them all, hence, only those classes  of  phenolic
substances that are abundant in the human diet and/or may exert important effects
on human health are discussed here.
Phenolic acids
The hydroxycinnamic acids and their derivatives are the most important subclass
of phenolic acids, but benzoic acid derivatives and hydrolysable tannins (polymers
of  gallic  and  ellagic  acids)  are  also  present  in  foods.  Some  common
hydroxycinnamates are p-coumaric, ferulic, sinapic, and caffeic acids; the latter is
thought to be the most abundant in the diet (Clifford, 2000). Phenolic acids exist
primarily as conjugates of e.g. sugars, polysaccharides, or organic acids, whereas
the free forms are less frequently observed in  nature.  The  quantitatively most
important conjugate of caffeic acid is its ester with quinic acid, 5-caffeoylquinic
acid (also known as chlorogenic acid). Phenolic acid conjugates are ubiquitously
distributed in the plant kingdom, e.g. in  fruits and vegetables. Especially high
concentrations are found in coffee, apples, citrus fruits and juices, and the bran of
cereal grains. Excessive coffee drinkers,  may  achieve a  daily  consumption  of
phenolic acids in excess of 1 g (Clifford, 2000). The intake of caffeic acid alone
was reported to be up to 983 mg per day in a southern German population, but
also as low as 5 mg per day in some individuals. However, the mean intake of
phenolic acids in this population was 222 mg/d (Radtke, Linseisen & Wolfram,
1998).
Flavonoids
In 1937, the group of Szent-Györgyi observed that certain flavonoids increased the
biological activity of ascorbic acid and could even heal scorbutic  pigs  and,
therefore, introduced the term ‘vitamin P’ for flavonoids (Bentsath, Rusznyak &
Szent-Györgi, 1937). However, the essentiality of flavonoids  for  humans  or
animals has never been proven and, therefore, the classification as a vitamin was
never warranted (Kühnau, 1976). Nevertheless, flavonoids exert a number of health
effects that may  justify  a  semi-essential status  for  these  compounds  (Lampe,
1999), as will be discussed below.24
The flavonoids are the most abundant class of dietary phenolic substances and,
as of 1999, more than 6400 different flavonoids have been identified (Harborne &
Williams, 2000). The basic structural feature of all flavonoids is  the flavane (2-
phenyl-benzo-g-pyrane) nucleus, a system of two benzene rings (A and B) linked
by an oxygen-containing pyrane ring (C;  Figures  4  &  5)  (Kühnau,  1976).
According to the degree of oxidation of the C-ring, the hydroxylation pattern of
the nucleus, and the substituent at carbon 3, the flavonoids can be categorized into
the subclasses flavones, isoflavones, flavanols (catechins), flavonols, flavanones,
anthocyanins, and proanthocyanidins (Figure 5) (Scalbert &  Williamson, 2000).
Some flavonoids, for example the flavonol quercetin, are widely spread in edible
plants, while others, e.g. the soy isoflavones genistein and daidzein, are restricted
to certain foodstuffs. Flavonols, flavanols, and anthocyanins are abundant in  the
human  diet,  while  flavones  and  isoflavones  are  less  common  (Scalbert  &
Williamson, 2000). In the Netherlands, Hollman & Katan (1999) found an average
consumption of flavonols and flavones of 23 mg/d and Arts and co-workers (2001)
estimated the average daily intake of catechins to be 50 mg. In a Japanese city, the
mean intake of isoflavones was 39 mg/d (Kimira et al., 1998).
Lignans
Plant lignans are a large class of phytochemicals that are formed by fusion of two
coniferyl alcohol residues and are structurally related to the lignins present in plant
cell walls. Lignans can be found throughout the plant kingdom, predominantly in
foodstuffs such as cereals, nuts, and seeds, where they occur as glycosides or in
free form (Mazur, 2000). Flaxseeds, with a content of 1-4% by weight, are one of
the richest dietary sources of the plant lignan secoisolariciresinol (Johnsson et al.,
2000; Eliasson et al., 2003). The average daily consumption of total plant lignans
in Finland was reported as 434 mg/d, where 396 mg/d was secoisolariciresinol and
38 mg/d was matairesinol (Valsta et al.,  2003). Sesame seeds and oils  contain
significant amounts of the lignans sesamin (up to  1.1%  by  weight in  oil)  and
sesamolin (up to 0.6% by weight in oil) (Kamal-Eldin  &  Appelqvist,  1994).
During the refining of sesame oils, sesamin is partially transformed to episesamin
while sesamolin is transformed to sesaminol and episesaminol (Fukuda et al.,
1994).25
Absorption and metabolism
The exact fate of  ingested  polyphenols  in  the  digestive  tract,  including  their
absorption and metabolism, remains largely unknown. Research in  this  area has
produced conflicting results, which are subject to debate. The current knowledge in
this regard may be briefly summarized as follows. Ingested polyphenols enter the
digestive system primarily in form of glycosides, although some aglycones may
be present. The glycosides may then be de-conjugated by the action of non-specific
b-glucosidases, present in the food itself or on the surface of or inside of mucosal
cells (Day et al., 2000; Aherne & O'Brien, 2002). Both aglycones and glycosides
have been reported to be absorbed. The conjugates are more hydrophilic than the
aglycones and the removal of the hydrophilic moiety appears to be a requirement
for the passive diffusion across the intestinal mucosa (Scalbert & Williamson,
2000; Aherne & O'Brien, 2002). It was also suggested that the intestinal sodium-
glucose transporter might carry phenolic glucosides through  the  intestinal  cell
 
 
O
 
O
 
O
 
H
 
O
 
O
 
O
 
O
 
H
 
O
 
O
 
O
 
O
 
H
 
O
 
O
 
Flavonols
Flavones
Flavanols
Isoflavones
Anthocyanidins
Flavanones
+
Figure 5. Basic chemical structures of the main flavonoid subclasses.26
wall. This has, however, not been proven in vivo (Aherne & O'Brien, 2002). The
polyphenols undergo extensive metabolism, mainly conjugation reactions, during
their passage through the enterocytes, e.g. O-methylation and/or conjugation with
glucuronides  and/or  sulphates.  Certain  transporter  proteins  (e.g. multidrug
resistance-associated protein-2) in the eneterocytes may actively transfer  the
glycosides back into the intestinal lumen. Absorbed polyphenols are transported in
the circulation and reach the  liver  via  the  portal  vein.  In  the  liver,  they  are
metabolised or secreted into the bile (Aherne & O'Brien, 2002). Un-absorbed or re-
excreted polyphenols reach the large intestine where they may undergo metabolism
to more simple compounds by the colonic microflora and the degradation products
(e.g. phenolic acids in  the case of flavonoid metabolism) may be absorbed by
passive diffusion. The polar, and therefore water-soluble, polyphenol glucuronides
and sulphates that escaped biliary excretion and  enterohepatic circulation  are
eliminated from the body by urinary excretion (Scalbert & Williamson,  2000;
Aherne & O'Brien, 2002; Murota & Terao, 2003; Spencer, 2003).
Following the ingestion of plant phenols, either as pure compound or as part of
a test meal, substantial amounts of conjugated metabolites, and sometimes of the
unconjugated  compound,  have  been  detected  in  human  blood  (Scalbert  &
Williamson, 2000). Hollman et al. (1997) reported the sum of quercetin aglycones
and metabolites in blood after the consumption of  onions  (containing 68  mg
quercetin) to reach a maximum of 0.74 mM. For a detailed overview over trials
reporting blood concentrations of flavonoids, the interested reader is referred to the
review article by Scalbert &  Williamson (2000). Nardini and colleagues (2002)
detected 91 ng/mL (~0.5 mM) caffeic acid (sum of conjugates and free form) in
blood plasma of volunteers 1 hour after they drank 200 mL of coffee.
Biological activities and health implications
Epidemiological studies provide evidence for a protective role of a diet rich in
vegetables, fruits, and wholegrain cereals against a range of degenerative diseases
including certain cancers, cardiovascular diseases, and diabetes mellitus  (Lampe,
1999; Segasothy & Phillips, 1999). Because of the proposed involvement of free
radical species in the aetiology of degenerative disorders (see above), the major
focus of research in the past has been on the effects of plant foods and compounds
isolated  from  them  on  the  antioxidant  defence system  (Lampe,  1999).  The
structural requirements for efficient  antioxidant  function  of  flavonoids  and
phenolic acids have been reviewed (Rice-Evans, Miller & Paganga, 1996). It was
also suggested that, owing to their one-electron reduction potentials, polyphenols
may spare endogenous antioxidants similar  to  the  recycling of  vitamin  E  by
ascorbic acid (Buettner, 1993). Phenolic acids, for example, have been reported to
efficiently scavenge free radicals in various model systems (Laranjinha, Almeida &
Madeira, 1994; Chen & Ho, 1997), to delay lipid oxidation, spare vitamin E, and
to regenerate tocopherol from its tocopheroxyl radical in human LDL, erythrocyte
membrane ghosts, and monocytic cells (Laranjinha et al.,  1995;  Nardini et al.,
1995; Nardini et al., 1998; Laranjinha & Cadenas, 1999; Liao & Yin, 2000). In a
rat model, caffeic acid spared vitamin E  and  enhanced the  resistance of  LDL27
towards oxidative stress (Nardini et al., 1997). A recent publication reported the
antioxidant potential of  polyphenols  from  apples  (quercetin, (+)-catechin, (-)-
epicatechin, chlorogenic acid, and others) in vitro and in vivo (Lotito & Frei,
2004). The authors found in vitro that flavonoids and phenolic acids from apples
delayed the oxidation of ascorbic acid and a-T in  blood  plasma. However, no
increased resistance to oxidation of endogenous antioxidants was found in blood
plasma collected from volunteers up to 4 hours after the consumption  of  five
apples (Lotito & Frei, 2004). This illustrates one of the weak spots in our current
knowledge about the antioxidant (and other biological) functions of polyphenols,
namely the sparse information on the metabolites that are present in  vivo. It  is
these  metabolites  that  may  exert  biological  effects,  rather  than  the  parent
compounds, which are conventionally employed in scientific experiments. Hence,
effects observed by the parent compounds in vitro may not readily translate into
similar effects in vivo. This  should  be kept in  mind  when interpreting results,
especially from in vitro studies with  pure phenolic substances. For  example, it
was shown that the flavonoid glycosides have lower antioxidant potentials than
their parent aglycones (Ross & Kasum, 2002) and similar results may be expected
for the conjugated metabolites and might explain the above findings.
Considering  the  relatively  low  blood  concentrations  of  dietary  phenolic
compounds and/or their metabolites compared to the much  higher  levels  of
endogenous antioxidants, doubts have been raised regarding their contribution to
the  antioxidant  defence  in  vivo (Williams,  Spencer  &  Rice-Evans,  2004).
Alternatively, it was suggested that the modulation of cell signalling pathways
might be important for their positive effects on  certain disorders. Polyphenols,
including flavonoids and their metabolites, were reported to modulate a range of
protein kinases (e.g. PKC) and transcription factors (e.g. nuclear  factor-kB),
thereby affecting cell proliferation and  apoptosis  (Orzechowski et  al.,  2002;
Williams, Spencer & Rice-Evans, 2004).
Phase I enzymes, such as cytochrome P450 isozymes, catalyse  oxidation,
hydroxylation, and reduction reactions by which they convert  xenobiotics  into
electrophiles in a preparatory step for their subsequent conjugation with water-
soluble  moieties  by  phase  II  enzymes  (e.g. sulphotransferases, glutathione
transferases, and UDP-glucuronosyltransferases) to enhance their excretion. Most
chemical carcinogens become carcinogenic only after activation by  phase  I
reactions. Consequently, reactions catalysed by CYP enzymes may not  only
activate some carcinogens, they may also result in the production of free radical
species. Plant polyphenols, on the other hand, have been shown to modulate the
activity of certain phase I and II enzymes (Lampe,  1999;  Orzechowski et  al.,
2002). For example, curcumin, the colouring principle in turmeric and mustard,
was found to dose-dependently inhibit the activities of CYP1A1, CYP1A2,  and
CYP2B1 in vitro and ex vivo in cells isolated from rats previously fed turmeric
(Thapliyal & Maru, 2001). The sesame lignan sesamin  inhibited  CYP3A  and
CYP4F2 activity in vitro in human and rat liver cells (Parker, Sontag & Swanson,
2000; Sontag & Parker, 2002). CYP3A is a major CYP in humans and known to
metabolise more than 50% of the commonly prescribed drugs (Cholerton, Daly &
Idle, 1992; Kliewer, Goodwin &  Willson,  2002). Dietary phenolic compounds28
have also been reported to inhibit a wide range of other enzymes,  such  as
lipoxygenase, cyclooxygenase, and phospholipase A2, to name but a few  (Raj
Narayana et al., 2001). Again, sesamin, as one example, was reported to  reduce
endogenous cholesterol biosynthesis by inhibition of HMG-CoA reductase activity
(Hirose et al., 1991) and episesamin was shown to increase cholesterol excretion
via induction of 7a-hydroxylase (Ogawa et al., 1995).
The dietary lignans secoisolariciresinol and matairesinol have  received much
attention from medical researchers because of their conversion by intestinal bacteria
into the mammalian lignans enterolactone  and  enterodiol.  Mammalian  lignans
have been identified in various bodily fluids (Axelson et al., 1982). Mammalian
lignans and other phyto-oestrogens (e.g. isoflavones) bind to oestrogen receptors
and  exert  weak  oestrogenic  activity,  thereby  altering  the  concentrations  of
endogenous  sex  hormones.  Hence,  phyto-oestrogens,  such  as  lignans  and
isoflavones, may have important effects on hormone dependent tumours (Lampe,
1999; Ross & Kasum, 2002). Indirect support of this notion can be derived from
epidemiological studies reporting a lower incidence of the hormone-related breast,
testicular, and prostate cancers in  countries  with  a  higher  intake  of  phyto-
oestrogens (Ross & Kasum, 2002).
Biopotency and bioavailability
The biopotency, or simply potency, of a substance is a measure of its biological
effects (Hoppe & Krennrich, 2000). For example, the biopotency of vitamin  E,
often referred to as its biological activity (Figure 1),  has  traditionally  been
assessed in fertility-restoration assays in rodents, such as the rat foetal resorption-
gestation test (Leth & Sondergaard, 1977). In these animal models, RRR-a-T has
a higher biological potency than all rac-a-T and the other E  vitamers (Bieri &
Evarts, 1974; Leth & Sondergaard, 1977; Leth & Søndergaard, 1983). Fertility-
restoration tests have been utilised because of the original discovery of vitamin E
as an essential factor for reproduction in  rats (Evans &  Bishop,  1922) and the
absence of appropriate  quantifiable  parameters in  humans.  Two  fundamental
prerequisites for the reliable determination of the biopotency of a substance in  a
certain species are (1) the exact knowledge of its  biological effects and (2) the
ability to measure these effects in the species of interest. In the case of vitamin E,
these basic requirements have been ignored for decades. Instead, the efficacy of
vitamin E to reverse infertility in  model animals has been determined and was
assumed to correlate with its biological functions  in  humans  (Hensley et  al.,
2004). Considering the dramatic increase in  our  knowledge about  the  diverse
biological functions of the different E vitamers (see  earlier), the  established
biological  potencies  and  their  relevance  for  humans  appear  questionable.
Consequently, properly designed vitamin  E  potency studies  in  humans  using
adequate functional endpoints are highly warranted. However, despite all scientific
progress since the original discovery of vitamin E, appropriate methods to measure
vitamin E biopotency in humans are still lacking  (Hoppe &  Kraemer, 2002).
Instead, its bioavailability, which relies on the assumption that the magnitude of29
its biological effect(s) depends on its concentration at the site of action,  is
commonly determined as a surrogate measure  for  its  biopotency  (Hoppe  &
Krennrich, 2000).
The term ‘bioavailability’ and the underlying concept were initially introduced
in the field of pharmacology, where bioavailability was defined as “the rate and
extent to which a drug reaches its site of action”. Because of the problems in the
quantification of a compound at its ‘site of action’, this concept was modified to
account for the fraction of an oral dose of a substance or its  metabolite(s) that
reaches the systemic circulation (Stahl et al., 2002). Thus, bioavailability can be
determined in a single-dose experiment by measuring the peak blood concentration
(Cmax), the time to reach the peak concentration (tmax), and the area under the blood
concentration time curve (AUC). The latter is the most reliable measure because it
takes into account the entire response over time, whereas Cmax measures only one
point in time. In a multiple-dose study, the compound of interest is given for at
least five times its half-life (t1/2) in the tissue intended for analysis (e.g. blood) to
establish the steady state concentration, which is the most important parameter in
this type of bioavailability study. A fundamental assumption of the bioavailability
concept is that the blood concentration and the biological activity of a compound
are proportional (Hoppe & Krennrich, 2000). However, this may not always be the
case. In scavenger receptor class B type I (SR-BI) knockout mice, for example, a-
T blood concentrations were increased while tissue levels remained normal or even
decreased (Mardones et al., 2002) and SR-BI knockout mice are reportedly prone
to female infertility and accelerated atherogenesis (Trigatti et al., 1999).
Bioavailability is influenced by  a multitude  of factors, including absorption,
distribution, metabolism, excretion, and bioactivity, which in  turn are governed
by a large number of parameters themselves (Stahl et al.,  2002). In the specific
case of vitamin E, bioavailability may be affected by  its  release from the food
matrix, the secretion of bile acids and pancreatic enzymes, the amount and type of
concurrently ingested fat, the dose and composition of vitamers consumed, the
action of a-TTP, the quantity of circulating lipoproteins, vitamin E  degradation
and excretion, the exposure to cigarette smoke, oxidative stress or other processes
consuming vitamin E, the presence of vitamin  E-regenerating antioxidants (e.g.
ascorbate), simultaneously consumed phenolic compounds,  and  many  other
parameters  (Stahl  et  al.,  2002).  The  influence  that  other  dietary  phenolic
compounds may exert on vitamin E bioavailability is in turn determined by their
own  bioavailability.  Eventually,  this  brings  us  to  the  fundamental  question
addressed in this thesis.30
How do dietary phenolic compounds affect the
bioavailability of vitamin E?
To answer the central question of this thesis, first of all one needs to identify the
characteristics  of  the  effects  of  dietary  phenolic  compounds  on  vitamin  E
bioavailability (increasing, decreasing, or not altering it). Then, one may seek for
and investigate the mechanism(s) by which these effects are facilitated. In this
thesis, these issues have been addressed using the following approach. In a series
of model experiments, phenolic compounds that occur frequently in  the human
diet were selected and screened for their potential effects on the bioavailability of
a- and g-tocopherol in blood plasma, liver and lung tissues of Sprague-Dawley
rats (Papers  I-VI). Next, substances with pronounced  effects on  vitamin  E
bioavailability in the rat model were selected and their impact on  the enzymatic
degradation of tocopherols to their water-soluble metabolites was tested in vitro,
using a human liver cell line and rat liver microsomes as models (Papers IV &
V). Finally, one group of compounds that had interesting effects in  the animal
model was tested in humans (Paper VII).
Animal model of vitamin E bioavailability
This section briefly describes the animal model employed to investigate the effects
of dietary polyphenols on the bioavailability of vitamin E.  For  a more detailed
description,  the  reader  is  referred  to  Papers  I-VI. A  semi-synthetic  diet,
containing low but adequate amounts of vitamin E and 0.2% cholesterol, was
prepared and used as control diet and as basis for the experimental feeds. The test
substances were incorporated into this basic diet at concentrations ranging from
0.1% to 0.4% (by weight) and these or control diets were fed to 21-23 days old
male Sprague-Dawley rats for 4 weeks. The low but adequate amounts of vitamin
E in the  diets  were utilized  to  avoid  saturation of  absorptive and  metabolic
processes, which could mask potential effects on vitamin  E  bioavailability. The
high doses of polyphenols, on the other hand, were used in order to  provoke
potential physiological reactions. The 4-weeks duration of the feeding period was
chosen to establish steady-state concentrations of vitamin E in the analysed tissues
(Bjorneboe, Bjorneboe & Drevon, 1987; Ingold et al., 1987). A secondary aim of
this project was to measure potential effects of dietary phenolic compounds on
cholesterol concentrations in the animals and therefore cholesterol was added to the
diets (see Papers I-VI).
Perhaps one of the first questions to cross one’s mind in regard to the approach
described above is: “Why study something in the rat that is expected to occur in
humans?” The answer is simple: Although the human diet contains a large variety
of phenolic compounds in significant quantities (see above), many of these have
not yet been approved for  human  consumption  as  isolated  substances by  the
authorities concerned. Furthermore, human studies require a tremendous input of
resources, such as money, labour, and time, and experimental conditions are much
more difficult  to  control  than  during  animal  experiments. For  these  reasons,31
human studies are not suitable for screening experiments and animal models are
generally preferred. The rat was chosen as model animal because its  physiology
and metabolism have  been  comprehensively studied  and  documented (Krinke,
2000) and organ samples are readily accessible. Also, rat studies are easy to repeat
and, thus, the results obtained can be reproduced without  much effort. What is
more, the physiological processes involved in nutrient digestion,  absorption,
transport, metabolism, and excretion in the rat are for the most part comparable to
those in humans. DeSesso and Jacobson (2001) discussed the factors  affecting
gastrointestinal absorption in  rats and humans in  a comprehensive review. The
alimentary tracts of both species consist, on a macroscopic level, of the  same
morphological  sections  (oesophagus,  stomach,  duodenum,  jejunum,  ileum,
caecum, colon, and rectum) that fulfil similar functions. In humans and rats, the
relative lengths (in percent of the total length of the intestinal tract) of the small
and large intestines (human, 81% and 19%; rat, 83% and 17%, respectively) are
similar, although  the  relative lengths of  the  subdivisions  may  deviate.  For
example, the jejunum stretches over ca. 38% of the human small intestine, while
the respective figure in rats is 90%. Another important difference between the two
species is that the relative surface area (normalised for body surface) of the human
small intestine, where the majority of absorptive processes takes place, is ~4 times
larger than that  of  the  rat.  Consequently,  dietary compounds  that  are poorly
absorbed in both species will be taken up to a greater  extent  in  humans  and
substances that are equally well absorbed will be taken up much faster by humans
(DeSesso & Jacobson, 2001). The uptake of alimentary substances is  not  only
determined by the absorptive surface, but also by the transit time of the intestinal
contents (chyme). The chyme transit time in the small intestine of both rats and
humans is 3-4 hours. However, the transit times for the large intestine differ and
are 2-4 days in humans and approximately 15 hours in rats. At  the microscopic
level, the alimentary tracts of humans and rats, e.g. in morphology and cell types,
is very similar (DeSesso & Jacobson, 2001). In accordance with these  general
similarities of the alimentary tracts of rats and humans, the substances tested in
the present work (Figure 6) were reported to be absorbed, metabolised,  and
excreted in both species (see Papers I-VI for details and respective references).
More support for the validity of the animal model can be derived from the fact that
the findings are largely in agreement with results from other in vitro and in vivo
models and, where available, from human studies (see Papers I-VII for discussion
and literature).
Effects of dietary phenolic compounds on vitamin E
bioavailability in the rat model
During  the  initial  phase  of  the  current  work,  a  variety  of  common  dietary
polyphenols was selected for the screening experiments (Figure 6), namely the
phenolic  acids  ferulic  and  caffeic  acid  and  the  phenolic  acid  conjugate  5-
caffeoylquinic acid (Papers I & III), the anthocyanin cyanidin-3-O-glucoside and
anthocyanin concentrates from blackcurrant and elderberry (Paper II), the flavanols
(+)-catechin and (-)-epicatechin (Paper IV and unpublished results), the lignans
sesamin, secoisolariciresinol diglucoside (SDG) and SDG-oligomer (Papers I  &32
VI),  the  curcuminoid  curcumin,  the  synthetic  antioxidant  butylated
hydroxytoluene  (BHT;  Papers  I  &  IV),  and  the  cereal  phenolic  lipids
alkylresorcinols (Paper V). In order to be able to compare the findings from the
different experiments despite of the variations in reference (control) values, the
results in Figure 7 are given as percent increase or decrease in the bioavailability of
a- and g- tocopherol.
Dietary plant lignans markedly affect vitamin E bioavailability in rats
The most striking result in Figure 7 is the dramatic increase in g-T  concentrations
in blood plasma (900%), liver (1350%) and lung tissues (1556%) in response to
supplementation with sesamin, which is in agreement with previous findings (see
Paper I and references therein). Sesamin was later shown to  effectively inhibit
tocopherol-w-hydroxylase activity in human and rat liver  cell  models  (Parker,
Sontag & Swanson, 2000; Sontag & Parker, 2002). The pronounced increase of g-
T bioavailability in response to  dietary sesamin was proposed to  result from a
reduced degradation and urinary excretion of the vitamer  (Parker,  Sontag  &
Swanson, 2000; Sontag & Parker, 2002), which was  later  confirmed in  male
Wistar rats (Ikeda, Tohyama & Yamashita, 2002).
In contrast to the findings for the sesame lignan sesamin, the flaxseed lignan
SDG, in monomeric and oligomeric form, reduced the  bioavailability of  both
tocopherols equally by ca. 50% (Paper VI). Consumption of a diet containing 10-
40% flaxseed previously resulted in a dose dependent reduction of a-T and g-T  in
liver and other tissues of rats, while lipid peroxidation, measured by the urinary
excretion of thiobarbituric acid reactive substances, increased (Ratnayake et al.,
1992). Although flaxseed lignans may undergo oxidative modification catalysed
by CYP enzymes, the major part of an ingested dose appears to be converted to
mammalian lignans  prior  to  absorption  and  no  appreciable amounts  of  plant
lignans  have  been  found  in  urine  from  flaxseed  lignan-supplemented  rats
(Niemeyer et al., 2003). The vitamin E-metabolising  enzymes as  well  as  the
hepatic a-TTP are unlikely to be involved in the effect brought about by dietary
flaxseed lignans because both discriminate between a-T and g-T  (Hosomi et al.,
1997; Sontag & Parker, 2002) and would therefore result in differential effects on
the two tocopherols.
The turmeric constituent curcumin has little effect on vitamin E
bioavailability in rats
Curcumin is regularly consumed in some populations and the daily intake from
curry powder in India may  be  in  the  range  of  0.4-1.5  mg/kg  bodyweight
(Srinivasan & Satyanarayana, 1988).  Curcumin  is  absorbed, metabolised,  and
excreted in the form of glucuronidated metabolites in  rats (Holder, Plummer &
Ryan,  1978).  When  tested  in  the  rat  model,  curcumin  only  changed  a-T
concentrations in lungs but had no statistical effect on vitamin E in the liver and
blood plasma (Paper I).33
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Figure 7. Changes (in percent) in the concentrations of a-tocopherol  (grey bars) and g-
tocopherol (white bars) in blood plasma, liver, and lungs of rats in response to 4 weeks
supplementation with phenolic compounds. Statistically significant changes  are given
in bold; n.a. = not  analysed.  All compounds  and extracts  were fed at the 0.2% dietary
level, except alkylresorcinols,  BHT, curcumin, and sesamin, fed at 0.4%, and SDG and
its oligomer fed at 0.1% in the diet. Due to the extreme values  for sesamin, the broken
bars do not reflect the actual proportions.35
Anthocyanins have little impact on vitamin E bioavailability in rats
Anthocyanins were previously reported to  possess  antioxidant  activity  and  to
counteract DNA damage and lipid peroxidaton in  rats (Tsuda, Horio &  Osawa,
1998;  Ramirez-Tortosa et al.,  2001).  Therefore,  cyanidin-3-O-glucoside and
anthocyanin-rich extracts of blackcurrant and  elderberry were tested  in  the  rat
model (Paper II). Neither the isolated compound nor the extracts exerted  any
major effects on  vitamin  E  bioavailability.  However, slight  increases in  a-T
concentrations in the livers and of g-T  in the lungs of cyanidin-3-O-glucoside-fed
rats were observed. The generally negligible outcome of this experiment may be in
part due to the small amounts of experimental substances given (as a consequence
of  the  impurity  of  the  polyphenolic  raw  material)  compared  to  the  other
experiments. The concentrations of anthocyanins fed in this study were comparable
to the average intake in humans (see Paper II for discussion and literature).
Dietary phenolic acids slightly improve vitamin E bioavailability in rats
In the animal model, dietary caffeic acid increased g-T in liver while its derivative,
5-caffeoylquinic acid, increased a-T in  lung  tissue.  This  is  similar to  previous
reports of an a-T sparing action of and the recycling of tocopheroxyl-radicals by
caffeic acid. 5-Caffeoylquinic acid appears to  be cleaved into  caffeic and quinic
acids prior to absorption. In response to dietary 5-caffeoylquinic acid, an increase
in blood concentrations of caffeic acid but not 5-caffeoylquinic acid was observed
in rats and humans. Consequently, its biological effects may be mediated by and
be similar to those of caffeic acid (see Paper III for discussion and references).
Ferulic acid, on the other hand, consistently exerted  no  effects on  vitamin  E
bioavailability in the rat model despite being a potent antioxidant in  vitro (see
Papers I & III). A study on the partitioning of ferulic acid in plasma and LDL
showed that the major fraction appears to be associated with albumin and only a
minor part with the lipid  fraction (Castelluccio et al., 1996). Therefore, ferulic
acid and tocopherols may exist in  separate compartments and their interactions
may be limited in vivo.
Dietary catechins enhance a-tocopherol bioavailability in rats
The flavanols (+)-catechin and (-)-epicatechin are stereoisomers that differ only in
the spatial configuration of the hydroxyl group on  ring C  (Figure 6) and were
reported to have comparable antioxidant capacities (Pedrielli &  Skibsted,  2002).
Both isomers markedly increased the bioavailability of a-T in blood plasma and
liver tissue in the present study. Interestingly, the 2R,3R-isomer (-)-epicatechin
also enhanced g-T bioavailability in both tissues whereas the 2R,3S-isomer (+)-
catechin was without effect on this tocopherol (Paper IV and unpublished results).
The effect on a-T is possibly due to antioxidant interactions between the flavanols
and the vitamin (see Paper IV for discussion and references). The increase in g-T
facilitated only by (-)-epicatechin may be  due  to  differential effects on  some
cytochrome P450 enzymes. Tea catechins were reported to affect a range of CYPs
including  CYP1A1,  CYP1A2,  CYP2B1,  and  CYP3A4  (Muto et al.,  2001;
Huynh & Teel, 2002; Vaclavikova et al., 2003). CYP3A was previously proposed
to  participate in  vitamin E  metabolism (Parker,  Sontag  &  Swanson,  2000)36
although the same group later suggested a role for CYP4F2 rather than CYP3A
(Sontag & Parker, 2002).
The synthetic antioxidant BHT enhances a-tocopherol bioavailability
Butylated hydroxytoluene (BHT) is a synthetic preservative frequently used in e.g.
convenience foods to preserve the oxidative stability of oils  and fats. In the rat
model, BHT markedly enhanced a-T bioavailability when fed at 0.2% (by weight;
Paper IV) and 0.4% (Paper I) dietary levels. Interestingly, BHT  reduced the
bioavailability of g-T to less than half the control values when given at 0.2% but
not at 0.4% in the diet. This discrepancy cannot be explained at present. Contrary
to our results, Simán & Eriksson (1996) found a dose dependent decrease in liver
concentrations of a-T in  BHT-fed female Sprague-Dawley rats. They attributed
this  effect  to  the  formation  of  pro-oxidative  metabolites  arising  from  the
catabolism of BHT by CYP enzymes, which were suggested to consume vitamin
E (Simán & Eriksson, 1996). In fact, BHT is metabolised by CYP and excreted in
urine in  form  of  water-soluble conjugates (Daniel &  Gage,  1965;  Bolton  &
Thompson, 1991). Following oral administration of BHT, female rats had higher
liver concentrations of BHT and excreted  larger  quantities  of  urinary  BHT-
metabolites at a faster rate than male rats treated in the same manner (Daniel &
Gage, 1965). The expression of CYP isozymes in an organism is far from static
and is known to vary depending on gender and age  (Rich  &  Boobis,  1997).
Therefore, it appears possible that  the  contrasting results  obtained  during  the
present work and by Simán & Eriksson (1996) result from gender  and/or  age
differences in BHT metabolism by CYP enzymes as seen in our young male and
their older female rats.
Cereal alkylresorcinols increase g-tocopherol bioavailability in rats
Alkylresorcinols are a class of cereal phenolic lipids predominantly present in the
outer layers of wholegrain wheat and rye and are absorbed and metabolised in
humans and rats (Ross, Kamal-Eldin & Åman, 2004). In the rat model,  dietary
supplementation with  cereal alkylresorcinols dose  dependently  increased g-T
concentrations in liver and lung tissues without altering a-T (Paper V) similar to
sesamin, although to a lesser extent. Because of the structural similarities between
tocopherols and alkylresorcinols it was hypothesised that they may share common
metabolic  pathways  and  competitively  inhibit  enzymatic  degradation  of
tocopherols (see Paper V and below).37
In vitro model of vitamin E metabolism
The discovery that sesamin inhibits the initial w-hydroxylation of tocopherols and
thereby reduces their degradation to carboxychroman metabolites (Parker, Sontag
& Swanson, 2000; Sontag & Parker, 2002) not only offered a ready explanation
for the observed increase in g-T  bioavailability in the sesamin-fed rats (Paper I),
but  also  opened  new  opportunities  for  the  investigation  of  some  of  the
mechanisms underlying the effects observed in the screening experiments. In order
to determine if the tested phenolic compounds  interfere with  the  side-chain
degradation of vitamin E, human HepG2 cells and  rat  liver  microsomes were
incubated for 48 hours with the respective polyphenol in the presence of g-T  or d-
T and the conversion to their respective 3'- and 5'-carboxychromanol metabolites
(Figure 3) was determined by GC-MS (Parker, Sontag &  Swanson, 2000). The
advantage of the in vitro model lies in the general ability of  HepG2 cells  to
metabolise polyphenols (Parker, Sontag & Swanson, 2000;  Parker &  Swanson,
2000; Sontag & Parker, 2002; O'Leary et al., 2003). Consequently, the effects
observed in the hepatoblastoma cell model may be  mediated  by  the  parent
compound and/or its metabolites in resemblance of the situation in vivo.
Alkylresorcinols and sesamin inhibit tocopherol metabolism in vitro
To clarify whether alkylresorcinols affect vitamin  E  metabolism or not,  HepG2
cells were incubated with 5 mM or 20 mM of mixed alkylresorcinols from rye or
synthetic pentadecylresorcinol (C15:0 alkylresorcinol) in the presence of g-T.  The
alkylresorcinol mixture and the pure compound both  dose-dependently inhibited
the formation of 3'- and 5'-g-carboxychromanol. The pure compound was a more
potent  inhibitor  of  tocopherol-w-hydroxylase  activity  than  the  mixed
alkylresorcinols (Paper V). With regard to the similar side-chains of tocopherols
and alkylresorcinols, it seems  likely  that  both  classes of  compounds  share a
common catabolic pathway and compete for the same metabolic enzymes. This is
supported by the recent discovery of urinary metabolites of alkylresorcinols in
humans, apparently resulting from b-oxidation of the side-chain (Ross,  Kamal-
Eldin  &  Åman,  2004).  Consistent  with  previous  reports  (Parker,  Sontag  &
Swanson, 2000; Sontag & Parker, 2002), sesamin, at a concentration of only  2
mM,  almost  completely  inhibited  tocopherol-w-hydroxylase  activity  and  the
degradation of g-T (Paper V). The inhibition of tocopherol side-chain degradation
by alkylresorcinols and sesamin gives a ready explanation for the increase in g-T
bioavailability observed in the  rat  model.  Sesamin  was  a  much  more  potent
inhibitor of tocopherol-w-hydroxylase activity  in  the  cell  model  than  the
alkylresorcinols and, accordingly, had a much more pronounced elevating effect on
g-T  concentrations  in  the  rats  (Papers  I  &  V).  Chemicals  with  a
methylenedioxyphenyl function, such as sesamin, are known to  form complexes
with CYP’s, thereby irreversibly inactivating the enzymes (Murray, 2000). The
dose-dependent effect of alkylresorcinols on tocopherol-w-hydroxylase activity in
the present work, on the other hand, suggests a (reversible) competitive inhibition
of CYP’s to be at the basis of the underlying mechanism (Paper V).38
BHT and (+)-catechin do not affect tocopherol metabolism in vitro
As  mentioned  before,  g-T is a much better  substrate  for  the  tocopherol-w-
hydroxylase pathway than a-T (Sontag & Parker, 2002). Hence, substances that
increase the bioavailability of a-T without affecting that of g-T  are unlikely to
exert this effect through modulation of the enzymes involved in tocopherol side-
chain degradation. However, the involvement of distinct  CYP  isozymes in  the
metabolism of the different E  vitamers cannot be ruled out  (Sontag &  Parker,
2002).  To  investigate  whether  the  tocopherol-w-hydroxylase pathway  was
involved in the increase in a-T bioavailability observed in the rats fed BHT and
(+)-catechin,  these  compounds  were  also  tested  in  the  in  vitro  model.  In
accordance with the above reasoning, neither BHT nor (+)-catechin  inhibited
tocopherol-w-hydroxylase activity (Paper IV).
Dietary sesame oil lignans decrease the urinary excretion of g-
T metabolites in humans
In the final stage of this project, the knowledge obtained in the animal and in vitro
models  was  applied  to  humans.  Based  on  the  drastic  increase  in  g-T
bioavailability in rats and the apparent inhibition of g-T  metabolism in liver cells
in response to sesamin, it was hypothesised that, in humans, oral application of
sesame lignans would result in a reduced excretion of urinary metabolites of co-
administered g-T. In order to test this, ten volunteers (5 females, 5 males) were
given two muffins prepared from unrefined sesame oil (equalling a dose of 94 mg
sesamin and 42 mg  sesamolin) or  corn  oil  (control) together with  a  capsule
containing  100  mg  a-  and  g-tocopherol  (50  mg  of  each  vitamer).  The
administered two sesame oil muffins contained a dose of 2.4 mg a-T and 13.0 mg
g-T  and  the  two  corn  oil  muffins  of  2.8  mg  a-T  and  13.2  mg  g-T.  The
tocopherols in the pills were stably labelled with different amounts of deuterium
(d6-a-T and d2-gT) in order to be able to differentiate between the newly ingested
and the endogenous tocopherols and their resulting metabolites in the blood and
urine samples that were collected for 72 hours.
The single dose of sesame lignans did not alter the bioavailability (measured as
Cmax, tmax,  or absolute concentrations at the given time  points) of a-T or g-T
(Paper VII). Comparing these results to those of Cooney et al. (2001), who found
a 19% increase in  blood  plasma  concentrations of  g-T  after only  3  days  of
supplementation with sesame seed enriched muffins (equalling a dose of 35  mg
sesamin and 13 mg sesamolin per day), suggests that a repeated intake of sesame
lignans is a prerequisite to  enhance g-T  bioavailability. This  seems even more
likely when compared to the 42% increase in g-T  blood concentrations in women
adding unrefined sesame oil to their habitual diets for 4 weeks (Lemcke-Norojärvi
et al., 2001).
Serum concentrations of tocopherol metabolites were slightly lower in subjects
eating the sesame instead of the corn oil  muffins, but  the differences were not
statistically significant. The responses in d0-a-CEHC and d0-g-CEHC were rather
weak compared to the steep rise and steady decline in d2-g-CEHC (Paper VII). g-39
CEHC was previously reported to  possess specific biological functions, e.g. as
natriuretic factor (Wechter et al., 1996) and anti-inflammatory agent (Jiang et al.,
2000), and its blood concentrations may therefore be subject to regulation (Galli et
al., 2003).
The urinary excretion of tocopherol metabolites was generally lower in subjects
receiving the sesame oil muffin treatment compared to those consuming corn oil
muffins. The urinary excretion of the newly ingested d2-g-T in  form of d2-g-
CEHC was significantly reduced from 6-12 hours (P<0.01) and at peak excretion
from 12-24 hours  (P<0.05)  following  the  treatment with  sesame oil  muffins
(Paper VII). In consequence, the total  amount of ingested d2-g-T recovered in
urine in form of d2-g-CEHC was significantly (P<0.05) lower after consumption
of sesame oil muffins (7.8 ± 3.7%) than corn oil muffins (12.3 ± 5.6%;  Paper
VII). Also the total urinary excretion of g-CEHC (sum of d2- and d0-g-CEHC)
was lower in subjects consuming sesame oil muffins than those consuming corn
oil muffins, but this effect was statistically significant only at  12  hours  after
treatment (P<0.02; Figure 8).
It  may  be  concluded  that  the  one-time  ingestion  of  sesame  oil  muffins
containing 136 mg sesame lignans significantly reduced the metabolism and
urinary excretion of newly ingested g-T in humans (Paper VII). Future studies
should also address the effects of a repeated intake of sesame lignans on vitamin E
bioavailability, metabolism, and excretion.
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Figure 8. Urinary excretion of g-CEHC (d2- + d0-g-CEHC; mmol/g creatinine) in subjects
(n=10) consuming sesame oil (solid line) or corn oil (dashed line) muffins.
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Some general remarks on vitamin E bioavailability
Changes in tocopherol concentrations could result from an altered availability of
vitamin E transport vehicles, the lipoproteins, in the blood. If that would be the
case, one would also expect similar changes in the  cholesterol content  of  the
lipoprotein fractions, because tocopherol and cholesterol concentrations are closely
correlated (Kayden & Traber, 1993; Perugini et al., 2000). However, the decreases
and increases in vitamin E bioavailability in the rat model were not accompanied
by corresponding changes in cholesterol levels (Papers I-VI). Hence, it  appears
unlikely that the observed effects on vitamin E bioavailability in this project were
due to altered lipoprotein concentrations.
The bioavailability of vitamin E might also be influenced by the ratio of a-T/g-
T in the diet. In earlier studies, g-T supplements increased blood concentrations of
both a-T and g-T in humans and rats (Handelman et  al., 1985;  Clément  &
Bourre, 1997), while a-T supplements  increased a-T  but  reduced g-T  blood
concentrations in humans (Melchert &  Pabel,  1998;  Huang  &  Appel,  2003).
Recently, the activation of PXR by all major forms of vitamin  E  was reported
(Landes et al., 2003). PXR is a nuclear receptor controlling the expression of drug
metabolising enzymes (Kliewer, Goodwin &  Willson,  2002).  In  this  manner,
vitamin E may induce the enzymes necessary for its  own metabolic breakdown
(Landes et al., 2003). Sontag & Parker (2002) reported a higher catalytic activity
of these enzymes towards g-T than a-T. Taken together, these studies suggest that
a-T  supplementation  activates  PXR  and,  thus,  induces  the  expression  of
tocopherol-w-hydroxylase, which then might preferentially degrade g-T.  However,
a conclusive explanation for the a-T elevating effect of g-T  supplements, other
than perhaps a simple  protection of a-T from oxidative decay by  g-T,  is  still
lacking.
In theory, at least one explanation for the increase in a-T concentrations due to
g-T supplementation seems possible, even though it has never been conclusively
proven to play a role in mammals. The only structural difference between a-T and
g-T lies in a methyl substituent in position 5 on the chromanol head (see Figure
1). While plants can methylate  g-T  to  a-T,  catalysed by  a  methyltransferase
(Munne-Bosch & Alegre, 2002), no such enzyme system has been reported in
mammals. Nevertheless, a few research groups have tried to  shed light  on  this
issue and gathered some evidence for a methylation of the desmethyl-forms of
vitamin E to  the  fully  methylated a-forms  in  vivo (Emmel  &  Celle,  1959;
Elmadfa et al., 1989; Goh et al., 1992; Qureshi et al., 2001). However, all  of
these studies have methodological limitations  that render the data interpretation
difficult. Hence, the conversion of g-T to a-T or the lack of conversion has yet to
be conclusively proven in vivo.41
Conclusions and future research
The findings of the present thesis can be summarised as follows:
• Certain  simultaneously  ingested  dietary  phenolic  compounds  alter  the
bioavailability of a- and g-tocopherol in rats:
- The tested anthocyanins, phenolic acids and derivatives, and curcumin have
only minor and varying effects on vitamin E bioavailability.
- Butylated hydroxytoluene, (+)-catechin, and (-)-epicatechin markedly increase
a-tocopherol bioavailability.
- Secoisolariciresinol diglucoside and its oligomer considerably decrease the
bioavailability of a- and g-tocopherols.
- Cereal alkylresorcinols and sesamin enhance g-T  bioavailability significantly
but do not alter that of a-T.
• The bioavailability of a- and g-tocopherol in rats can be affected to a different
extent in different tissues.
• Butylated  hydroxytoluene  and  (+)-catechin  do  not  affect  the  side-chain
degradation of tocopherols in vitro.
• Sesamin almost completely inhibits the side-chain degradation of tocopherols
in vitro.
• Cereal alkylresorcinols dose-dependently reduce the side-chain degradation of
tocopherols in vitro.
• Singular consumption of sesame oil muffins reduces the urinary excretion as g-
CEHC of concurrently ingested g-tocopherol in humans.
As is so often the case in science, one starts research with a single question. As
one attempts to find the answer to that one question, more and more questions
arise along the way. Eventually, one may end up a tiny step closer to the answer
to the original question, but far away from the answers to a plethora of new ones.
One such subject for future research relates to the still unknown mechanisms by
which BHT and the catechins increased the concentrations of a-T in  rats. Since
these compounds did not  inhibit  vitamin  E  metabolism, other mechanisms are
likely to be involved and deserve investigation. The  mechanisms  by  which
polyphenolic chemicals might  spare a-T  may  involve  (1)  scavenging of  free
radical species that consume a-T; (2) inhibition of enzyme systems that produce
free radicals (e.g. lipoxygenase, cyclooxygenase, and CYP’s); (3)  induction  of
antioxidant  enzyme  systems  (e.g. catalase  and  glutathione  peroxidase);  (4)
enhancement of vitamin E absorption; (5) increased expression of a-TTP through
induction  of  (i)  gene  expression  and/or  (ii)  translational  processes;  and  (6)
improvement of the binding capacity of a-TTP.  Appropriate  experiments  to42
investigate these mechanisms are highly  warranted. Furthermore, future research
should not only try to substantiate and characterise the interactions of vitamin E
with co-administered phenolic compounds, it should also consider the metabolic
interactions between different simultaneously ingested E vitamers.
The animal models employed in this thesis largely made use of pharmacological
doses of the tested compounds, in order to identify interactions with  vitamin  E
bioavailability. In continuation of the work initiated with  the  human  study
reported in Paper VII, it would be of particular interest to study in the future the
interactions with vitamin E bioavailability of the effective compounds at common
dietary  levels,  in  order  to  assess  the  importance  of  the  observed  metabolic
interactions for human nutrition.
Among the broader questions that frequently came up during the course of this
work has been one that is as yet unanswered: “What makes vitamin E a vitamin?”
For decades, the antioxidant activity of vitamin E has been the sole  focus  of
vitamin E research. But can we really replace vitamin  E  with  any other potent
lipid-soluble antioxidant? This seems unlikely given that in recent years the non-
antioxidant functions of vitamin E have become evident and unique properties of
specific vitamers and their metabolites have been revealed (see earlier). A  related
question of particular interest is: Which of the E  vitamers is/are indispensable?
The most recent dietary reference intakes for vitamin E, given out by the Food and
Nutrition Board of the Institute of Medicine (2000), consider a-tocopherol to be
the only essential vitamer. However, until the exact physiological tasks of  all
vitamers and their metabolites have been identified and characterised, it  appears
premature to disregard any form of vitamin E.
It was pointed out before, that plants are capable of converting g-tocopherol to
a-tocopherol by a single methylation-reaction and that no such g-tocopherol
methyltransferase has been reported in animals. The existence of such an enzyme
in mammals would give some credence to the sole essentiality of a-tocopherol,
while its absence may hint toward physiological roles of the desmethyl vitamers.
However, sound experiments substantiating or disproving the in vivo conversion
of the desmethyl- to the a-vitamers are highly warranted.
Finally,  it  should  be  borne  in  mind  that  we  only  measure  vitamin  E
bioavailability as a marker of its biopotency.  High  blood  concentrations of
vitamin E do not necessarily reflect high levels in tissues and its presence in the
blood alone does not guarantee its biological activity. Hence, vitamin E research
would greatly benefit from the development of a reliable in vivo-assay for vitamin
E-biopotency. However, for the time being the bioavailability concept is the most
accurate tool to our disposal.43
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